SCHEMBL6715528

SCHEMBL6715528

Cc1cccc(NC(=O)C(NC(=O)O)c2ccccc2)c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 1/20 0.53
KMT2A Q03164 6/20 0.51
MEN1 O00255 5/20 0.51
ALDH1A1 P00352 3/20 0.51
L3MBTL1 Q9Y468 2/20 0.51
MAPT P10636 4/20 0.51
TP53 P04637 1/20 0.51
KDM4E B2RXH2 1/20 0.51
EGFR P00533 1/20 0.49
MMP1 P03956 1/20 0.49
MMP2 P08253 1/20 0.49
MMP9 P14780 1/20 0.49
MAOA P21397 1/20 0.49
MAOB P27338 1/20 0.49
POLB P06746 2/20 0.49
KCNK3 O14649 1/20 0.49
KCNK9 Q9NPC2 1/20 0.49
RXFP1 Q9HBX9 1/20 0.49
TDP1 Q9NUW8 1/20 0.48
LMNA P02545 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6719138 0.88 KMT2A (0.59) KMT2AMEN1ALDH1A1MAPTTP53
SCHEMBL6715920 0.86 POLB (0.61) HSD17B10KMT2AMEN1ALDH1A1MAPT
SCHEMBL8336972 0.85 CTSS (0.57) ALDH1A1MAPTTP53KDM4E
SCHEMBL6719076 0.84 MAPT (0.56) KMT2AMEN1ALDH1A1MAPTTP53
SCHEMBL6726960 0.83 ALDH1A1 (0.51) KMT2AMEN1ALDH1A1L3MBTL1MAPT
SCHEMBL6718828 0.83 ALDH1A1 (0.61) KMT2AMEN1ALDH1A1MAPTPOLB
SCHEMBL6715851 0.82 ALDH1A1 (0.59) KMT2AMEN1ALDH1A1L3MBTL1MAPT
SCHEMBL28653848 0.81 ALDH1A1 (0.58) HSD17B10KMT2AMEN1ALDH1A1L3MBTL1
SCHEMBL20335082 0.81 FPR2 (0.59) HSD17B10KMT2AMEN1ALDH1A1L3MBTL1
SCHEMBL6719400 0.81 ULK1 (0.51) KMT2AMEN1ALDH1A1MAPTTP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040152741-A1 Arylglycine derivatives and their use as glycine transport inhibitors NPS ALLELIX CORPORATION (CA) 2004-08-05 US disclosed
WO-2004022534-A1 ARYLGLYCINE DERIVATIVES FOR USE AS GLYCINE TRANSPORT INHIBITORS NPS ALLELIX CORP. (CA) 2004-03-18 WO disclosed
WO-2004022528-A2 ARYLGLYCINE DERIVATIVES AND THEIR USE AS GLYCINE TRANSPORT INHIBITORS NPS ALLELIX CORP. (CA) 2004-03-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040152741-A1 Arylglycine derivatives and their use as glycine transport inhibitors SLC1A2, SLC1A1, SLC7A11 HSD17B10 955/4885KMT2A 1656/4885MEN1 2822/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.